Variant position: 39 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 296 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SLPLAALNMRVRRRLSLFLN VRTQVAADWTALAEEMDFEYL
Gorilla SLPLAALNMRVRRRLSLFLN VRTQVAADWTALAEEMDFEYL
Rhesus macaque SLPLAALNMRVRRRLSLFLN VRTQVAADWTALAEEMDFEYL
Chimpanzee SLPLAALNMRVRRRLSLFLN VRTQVAADWTALAEEMDFEYL
Mouse SIPLVALNVGVRRRLSLFLN PRTPVAADWTLLAEEMGFEYL
Rat SLPLVALNVGVRRRLSLFLN PRTTAAADWTSLAEEMGFEYL
Pig SLPLAALNVRVRHRLSLFLN VRTQVAADWTGLAEEMNFEYL
Bovine SLPLAALNVRVRRRLSLFLN VRAPVAADWTVLAEAMDFEYL
Sheep SLPLAALNVRVRRRLSLFLN VRAPVAADWTVLAEAMDFEYL
Chicken SVPMVALNYGVRRRLGLYLN PRAATAADWTALAEKLGHDYL
Xenopus tropicalis SIPLVALNYNVRHRLSLYLN PNAVVAAGWTQLAEEMGYDYL
Zebrafish AIPVTALNCSFRKKLGLFLN PTNTVAADWRTVAELMDFTYL
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 296 Myeloid differentiation primary response protein MyD88
Oncogenically active MYD88 mutations in human lymphoma.
Ngo V.N.; Young R.M.; Schmitz R.; Jhavar S.; Xiao W.; Lim K.H.; Kohlhammer H.; Xu W.; Yang Y.; Zhao H.; Shaffer A.L.; Romesser P.; Wright G.; Powell J.; Rosenwald A.; Muller-Hermelink H.K.; Ott G.; Gascoyne R.D.; Connors J.M.; Rimsza L.M.; Campo E.; Jaffe E.S.; Delabie J.; Smeland E.B.; Fisher R.I.; Braziel R.M.; Tubbs R.R.; Cook J.R.; Weisenburger D.D.; Chan W.C.; Staudt L.M.;
Cited for: INTERACTION WITH IRAK4; VARIANTS MET-39; GLY-136; ILE-136; PHE-204; ARG-205; CYS-206; THR-207; ARG-209; THR-219; ASN-230; PRO-252 AND PRO-281; CHARACTERIZATION OF VARIANTS ARG-209; THR-219; ASN-230; PRO-252 AND PRO-281;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.